-        Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not yet reached

-        Patent rights secured for TJ-L14B/ABL503 in Eurasia until 2039

ROCKVILLE,...